Yew Bio-Pharm Group, Inc. (OTCMKTS:YEWB) Files An 8-K Regulation FD DisclosureItem 9.01Regulation FD Disclosure
On September 25, 2018, the Company issued a press release announcing that the Company has submitted its application to list its common shares on the NASDAQ Capital Market. The listing of the Company’s common shares on NASDAQ remains subject to the approval of NASDAQ and the satisfaction of all applicable listing and regulatory requirements, including the share-price requirements which the company does not meet at this time. A copy of the press release is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
This disclosure does not constitute an offer to sell, or the solicitation to buy, any such security.
| Item 9.01 | Financial Statements and Exhibits. |
(s)
Yew Bio-Pharm Group, Inc. ExhibitEX-99.1 2 f8k092518ex99-1_yewbiopharm.htm PRESS RELEASE,…To view the full exhibit click here
About Yew Bio-Pharm Group, Inc. (OTCMKTS:YEWB)
Yew Bio-Pharm Group, Inc. is a grower and seller of yew trees and manufacturer of products made from yew trees in China. The Company operates through five segments: traditional Chinese medicine (TCM) raw materials, which is engaged in the production and sale of raw materials used for medicinal application in the pharmaceutical industry; yew trees, which is engaged in the cultivation and sale of yew seedlings, yew trees and potted yew trees; handicrafts, which is engaged in the manufacture and sale of furniture and handicrafts made of yew timber; wood ear mushroom, which includes the sale of wood ear mushroom, and others, which includes the sale of yew candles and pine needle extracts. It is engaged in processing and selling yew raw materials used in the manufacture of TCM; growing and selling yew tree seedlings and mature trees, including potted miniature yew trees; manufacturing and selling furniture and handicrafts made of yew tree timber, and selling agricultural products.